about
Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular diseaseEndothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic DiseasesPotential of non-coding RNA as biomarkers in heart failureCardiac fibrosis in myocardial infarction-from repair and remodeling to regenerationFacts and updates about cardiovascular non-coding RNAs in heart failureRegulatory Mechanisms of the Molecular Pathways in Fibrosis Induced by MicroRNAsThe fibrosis-cell death axis in heart failureCurrent Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure.Loss of microRNA-124 expression in neurons in the peri-lesion area in mice with spinal cord injuryMicroRNAs in placental health and diseaseA new Agkistrodon halys venom-purified protein C activator prevents myocardial fibrosis in diabetic ratsDiabetes-associated cardiac fibrosis: Cellular effectors, molecular mechanisms and therapeutic opportunities.Long non-coding RNAs display higher natural expression variation than protein-coding genes in healthy humansInhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure OverloadIdentification of cardiomyopathy associated circulating miRNA biomarkers in patients with muscular dystrophy using a complementary cardiovascular magnetic resonance and plasma profiling approachBlood-based microRNA signatures differentiate various forms of cardiac hypertrophy.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodellingCrucial Role of miR-433 in Regulating Cardiac FibrosisExpression signature of lncRNAs and their potential roles in cardiac fibrosis of post-infarct mice.Luteolin-7-diglucuronide attenuates isoproterenol-induced myocardial injury and fibrosis in miceIdentification of the Spinal Expression Profile of Non-coding RNAs Involved in Neuropathic Pain Following Spared Nerve Injury by Sequence Analysis.MicroRNAs in myocardial infarction.Evolving targeted therapies for right ventricular failure.Candidate biomarkers in heart failure with reduced and preserved ejection fraction.miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart.miR-21 promotes fibrosis in an acute cardiac allograft transplantation model.Noncoding RNAs in Heart Failure.What Is New in the miRNA World Regarding Osteosarcoma and Chondrosarcoma?Local microRNA-133a downregulation is associated with hypertrophy in the dyssynchronous heart.Acupuncture may exert its therapeutic effect through microRNA-339/Sirt2/NFκB/FOXO1 axis.Dawn of the Epi-LncRNAs: new path from Myheart.Getting Old through the Blood: Circulating Molecules in Aging and Senescence of Cardiovascular Regenerative Cells.Decreased expression of long non-coding RNA LOC728290 in human hepatocellular carcinoma.Systematic analysis of the expression profile of non-coding RNAs involved in ischemia/reperfusion-induced acute kidney injury in mice using RNA sequencing.Interleukin-10 Inhibits Bone Marrow Fibroblast Progenitor Cell-Mediated Cardiac Fibrosis in Pressure-Overloaded Myocardium.MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload.LET's sponge: How the lncRNA PFL promotes cardiac fibrosis.Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives.MicroRNAs Mediate Beneficial Effects of Exercise in Heart.Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
P2860
Q26739721-8DE0B01C-5E21-4959-A82F-BA0740066151Q26748338-D51EFE24-B226-4B3C-B255-8FAF1C05240CQ26784127-E2842D08-189C-4789-9E3B-B8AB4F85FDAFQ28068468-FAA18EF3-86B6-467C-97C4-A50DE780D99FQ28072307-22589AD7-3B6E-497C-9341-80DE5A9834F1Q28072792-928AAB03-F4F8-405B-8D00-E345A448CF3DQ28076570-0C8DE23E-710E-4D9B-AD63-580310539C55Q33595504-3BD3FB67-065E-4F41-8972-A06679AC4CA7Q35969720-7166FA6E-86EB-462C-9957-EEA265F62F87Q36118260-B5B1212B-B9E9-4D72-9EE3-5D6E948FF7B2Q36307139-3DB8EB33-DAD9-47D0-BE7E-0184517D31CFQ36479405-B812AC6B-52F2-4ECD-9A59-606C92A7719CQ36517502-6392A73C-C57E-4FB9-B18F-F5FF9C12D220Q36634367-1DB77328-221F-41DA-873A-DA6ABCDD74BDQ36875975-F14C6B4B-6310-4948-9C7C-9889D82C4705Q37074084-E8D30852-90C4-405F-8B93-D07DD6588E74Q37096257-E2322FFD-71A5-4752-BBFD-7CBBE7BDD634Q37291267-088BAB48-68B9-46CB-8079-3AAEA9965072Q37626818-2FD33582-20EB-4830-ADF6-D8E5AAD50D63Q37688764-75A5AC30-A885-4597-A532-4C0FADE3C1CBQ37735123-36A85EA3-5C7A-4E6A-AAAE-28DDFD993322Q38289373-EF9D564F-52F8-412F-92F7-CA9A5026519BQ38559308-094BA12C-ABD5-41C4-BDEA-46B1D0740E7EQ38572500-20030054-44FE-4AF3-945D-AC831D9008F8Q38591803-F7F691D2-0B02-474A-98F9-1D4D36C9DE57Q38795098-0C804C37-F0A1-4384-9D80-18E5DF256F4AQ39044115-40399DE1-D728-4DD6-987C-7E3DD60E50FFQ39168132-360ED5FE-B078-4A0A-9458-6B16A67CA474Q41239272-FDD8241A-633C-4CB9-AAFC-671FDB9626E1Q41393514-C87EFB08-007F-4155-AFC0-4E457064EE5EQ42012946-64668F78-DADC-4449-AE19-4C8C4895983FQ43192139-24D14A3A-C2FC-4C47-949C-C36F0002D34DQ47143020-57982A30-F823-496A-95F3-5FB4E8FF0AF8Q47147571-F522DF38-5110-47A4-A5DE-0299B614CD29Q47969185-A4592995-59FC-43C5-8203-FBF89BD200A4Q49379816-AB57560B-DDBD-4F22-BC6B-A6614FB02D02Q49788233-198A1223-DF36-4D2C-B9A7-11FF2458B9DFQ51041886-C8D766A3-8281-4193-A982-3E56E3FFDDA0Q51787118-B1C5A440-30CB-472A-A08B-7B8C098AD454Q52536468-3CAF0B7E-2949-4A69-9174-C798102EC948
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Noncoding RNAs and myocardial fibrosis.
@en
type
label
Noncoding RNAs and myocardial fibrosis.
@en
prefLabel
Noncoding RNAs and myocardial fibrosis.
@en
P2860
P1476
Noncoding RNAs and myocardial fibrosis.
@en
P2093
Thomas Thum
P2860
P304
P356
10.1038/NRCARDIO.2014.125
P407
P577
2014-09-09T00:00:00Z